Cellectis Inc. (CLLS) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please stand by. Your program is about to begin. If you need audio assistance during today's program, please press star zero. Good day, everyone, and welcome to today's Selectus full year 2024 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question anytime by pressing the star, then the one key on your telephone keypad. You may withdraw yourself from the queue by pressing the star 2 key. Please note, today's conference is being recorded. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Arthur Strill. Please go ahead. Good morning, and welcome, everyone, to Selectus' fourth quarter and full year 2024 business update and financial results conference calls. Joining me on the call today are Dr. André Choulika, our Chief Executive Officer, and Dr. Adrienne Kilcoyne, our Chief Medical Officer. Yesterday evening, Selectus issued a 6K and press release reporting our financial statements for the 12-month period ended December 31, 2024, and a business update. The report and press release are available on our website at selectus.com. As a reminder, we will make statements regarding selected financial outlook, including the sufficiency of cash to fund operations, in addition to our manufacturing, regulatory, and product development status, as well as product development status of our licensed partners. These forward statements which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and un...